RARA and acute promyelocytic leukemia: ATO is a first-line therapeutic agent for APL, which is characterized by a typical chromosomal translocation t(15; 17) (q22; q21) resulting in the formation of the fusion protein, promyelocytic leukemia-retinoic acid receptor α (PML-RARα).